In Alexs latest video for his Status Report series, he explores the possibility that Ozempic could someday lose its trademark if the name becomes the generic term for an entire category of product
Shiara Ortiz-Pujols, the director of obesity medicine at Northwell's Staten Island University Hospital, told The Post
most formulations are not established as safe at clinical doses in pregnancy
Phase 2 trial data (published in the New England Journal of Medicine, 2023) have demonstrated significant weight loss and improvements in glycaemic markers, but the complete safety profile including the precise risk of low blood sugar continues to be characterised
Mike Haney: That makes perfect sense coming from a clinician, but I'm curious why is that the case for the patient
Nobody knew where it would lead, and several of the participants are unfortunately now deceased